A new paradigm for tumor immune escape: β-catenin-driven immune exclusion

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

(2015) Stefani Spranger et al.   NATURE

Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer – Review of current data

(2015) Mark S. Swanson et al.   ORAL ONCOLOGY

Complete Loss of PTEN Protein Expression Correlates with Shorter Time to Brain Metastasis and Survival in Stage IIIB/C Melanoma Patients with BRAFV600 Mutations

(2014) A. D. Bucheit et al.   CLINICAL CANCER RESEARCH

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment

(2014) Stefani Spranger et al.   Journal for ImmunoTherapy of Cancer

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

(2013) Omid Hamid et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects

(2013) John Stagg et al.   Therapeutic Advances in Medical Oncology

BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

(2012) C. Liu et al.   CLINICAL CANCER RESEARCH

β-Catenin Signaling Controls Metastasis in Braf-Activated Pten-Deficient Melanomas

(2011) William E. Damsky et al.   CANCER CELL

BrafV600E cooperates with Pten loss to induce metastatic melanoma

(2009) David Dankort et al.   NATURE GENETICS

Regulated Expression of a Tumor-Associated Antigen Reveals Multiple Levels of T-Cell Tolerance in a Mouse Model of Lung Cancer

(2008) A. F. Cheung et al.   CANCER RESEARCH